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AbstrAct
Background Patients with severe aortic stenosis 
(AS) have a reduced life expectancy and quality of life 
(QoL), owing to advanced age and the presence of 
multiple comorbidities. Currently, there is no AS-specific 
QoL measurement tool, which prevents an accurate 
assessment of how this chronic condition and its 
treatment affect patients. The Toronto Aortic Stenosis 
Quality of Life Questionnaire (TASQ) was developed in 
order to address this deficiency.
Methods The present trial protocol was designed to 
enable validation of the TASQ, which has been produced 
in five languages (English, French, German, Italian and 
Spanish) to increase usability. Patients with severe AS who 
are undergoing surgical aortic valve replacement (SAVR) or 
transcatheter aortic valve implantation (TAVI) will be asked 
to complete the TASQ and, for comparative purposes, 
the Kansas City Cardiomyopathy Questionnaire and the 
general health-related QoL Short Form-12 questionnaire. 
The questionnaires will be completed prior to the 
intervention, at discharge, as well as at 30 days and 3 
months follow-up. A total of 290 patients will be recruited 
across one Canadian and nine European centres. Overall, 
the protocol validation aims to include 120 patients 
undergoing transfemoral TAVI (TF-TAVI), 120 undergoing 
SAVR and up to 50 being treated medically. The primary 
objective of the registry is to validate the TASQ in five 
different languages. The secondary objective is to assess 
the utility of the TASQ for assessing differences in QoL 
outcome between patients undergoing TF-TAVI, SAVR or 
medical management for their AS.
Discussion Validation and roll-out of the TASQ will enable 
clinicians to capture an accurate assessment of how AS 
and its management affects the QoL of patients and will 
help them to determine the most appropriate treatment 
strategy for individual patients.
Trial registration number NCT03186339
InTroDuCTIon
Degenerative aortic stenosis (AS) is typically 
characterised by progressive calcification 
of the aortic valve, resulting in increased 
strain on the left ventricle. Once symptoms 
Key Questions
What is already known about this subject?
 ► Patients with severe aortic stenosis (AS) have a 
reduced life-expectancy and quality of life, ow-
ing to advanced age andthe presence of multiple 
comorbidities.
 ► Currently, many different scales existto assess 
Quality of Life (QoL) in patients with cardiovascular 
disease. However, there is no AS-specific QoL mea-
surement tool, which prevents anaccurate assess-
ment of how this chronic condition and its treatment 
affect patients.
What does this study add?
 ► The Toronto Aortic Stenosis Quality of Life 
Questionnaire (TASQ) was developed in order to 
address this deficiency of anAS- specific QoL mea-
surement tool.
 ► As with any novel questionnaire, validationof TASQ 
is required. In this protocol we describe the meth-
ods that will be used to validate the TASQ in patients 
with severe AS being treated with surgicalaortic 
valve replacement (SAVR), transcatheter aortic valve 
replacement (TAVI) or medical management.
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Key Questions
How might this impact on clinical practice?
 ► Validation and roll out of the TASQ will enable clinicians to capture 
an accurate assessment of how AS and its management affects the 
QoL of patients and will help them to determine the most appropri-
ate treatment strategy for individual patients.
develop, the condition has usually reached such a severity 
that prompt intervention is essential. Without treatment, 
survival rates range from 15% to 50% at 5 years.1 Treat-
ment with surgical aortic valve replacement (SAVR) has 
generally been the procedure of choice, while transcath-
eter aortic valve implantation (TAVI) has been developed 
as an alternative for patients who are at high or prohibi-
tive risk for surgery.2 In some cases, an individual may be 
too sick or frail to undergo any form of invasive proce-
dure. Such patients are treated with medication due to 
the limited chance of improvement after any form of 
surgical or interventional treatment.
Understanding how an illness can impact a patient’s 
life is imperative to planning treatment strategies that 
will optimise the management of their symptoms and to 
determine the patient’s satisfaction with the treatment 
they receive.3 4 While there is a great deal of informa-
tion about survival and morbidity outcomes after aortic 
valve replacement, there is a lack of comprehensive data 
regarding quality of life (QoL) changes before and after 
the intervention.5–7 This is particularly significant in the 
setting of severe AS, where patients often have a reduced 
life expectancy, which affects their day-to-day physical 
and emotional condition. Furthermore, the cost of the 
procedure requires an assessment of the real value of 
the therapy taking into account the patient’s and family 
perception of the benefit, that has an additional value.
It is important, therefore, to capture the physical and 
psychological disruptions caused by chronic diseases and 
their treatments. The level of interference varies by disease 
and by the different treatments received.8 Many different 
scales exist to assess QoL in patients with cardiovascular 
disease, including the Kansas City Cardiomyopathy Ques-
tionnaire (KCCQ),9 the Seattle Angina Questionnaire 
(SAQ),10 the Minnesota Living with Heart Failure ques-
tionnaire11 and the MacNew heart disease health-related 
QoL questionnaire.12 There are also a number of generic 
health-related QoL questionnaires, including the widely 
used Short Form (SF)-12,13 the Euro-QoL five dimensions 
(EQ-5D)14 and the Illness Intrusiveness Ratings Scale 
(IIRS).8 The KCCQ is perhaps the most relevant scale for 
application to patients with AS, as there are many simi-
larities in the symptoms of AS to those of heart failure 
(HF). In a number of analyses of patients undergoing 
valve replacement, Arnold et al demonstrated a level 
of validity of the KCCQ.15–17 However, the treatment of 
AS differs substantially to that of HF, which significantly 
affects changes in QoL after any intervention.
In order to attain a more accurate picture of QoL for 
patients with severe AS before and after treatment, the 
Toronto Aortic Stenosis Quality of Life Questionnaire 
(TASQ) was developed.18 This questionnaire takes into 
account AS-specific symptoms and how they affect a 
patient’s physical and mental well-being, as well as eval-
uating the patient’s assessment of their general health. 
As with any novel questionnaire, validation of TASQ is 
required. Here, we describe the methods that we will use 
to validate the TASQ in patients with severe AS being 
treated with SAVR, TAVI or medical management. To 
facilitate dissemination of the questionnaire to multiple 
countries, it will be validated in five different languages 
using the standardised methodology described.
MeTHoDs anD analysIs
study design
This is a prospective, multicentre, multinational registry 
with a follow-up period of 3 months. A total of 290 
patients will be recruited across 10 centres, nine centres 
in Europe (Austria,1 France,2 Germany,1 Italy,2 Spain2 
and the UK1) and one centre in Canada. Overall, this 
validation will include 120 patients undergoing trans-
femoral-TAVI (TF-TAVI) (Edwards Lifesciences, Irvine, 
California, USA), 120 patients undergoing (minimally 
invasive or full sternotomy) SAVR with any commercially 
available valve and up to 50 patients being treated medi-
cally. To avoid geographical or cultural variability, special 
attention will be payed on an even distribution of the 
patients enrolled within the centres. The TASQ has been 
produced in English and was validated in five languages—
English, French, German, Italian and Spanish—to ensure 
that patients can receive the questionnaire in their native 
language. Translation was conducted by members of all 
target countries including two forward and one back-
ward translation steps followed by cognitive interviews 
on five patients with a heart condition and final proof-
reading. For each language, 58 patients will be recruited. 
For comparative purposes, patients will be required to 
complete the TASQ, as well as the KCCQ and SF-12, at 
baseline, predischarge, as well as at 30 days and 3 months 
follow-up. The three questionnaires will be given to the 
patient sequentially, but in a random order.
To be included in the study, all patients need to be 
elective patients with severe symptomatic AS, have no 
major cognitive impairment and be able to provide 
written consent to participate in the study. Consent will 
be obtained by a study nurse at baseline, prior to TAVI/
SAVR procedure and after the patient has had a chance 
to read and understand the patient information leaflet 
provided.
Development of the TasQ
The TASQ was created by an interdisciplinary team of 
clinicians and patients with AS who were being assessed 
for TAVI procedures. Overall, 333 patients with AS were 
identified and interviewed to understand their current 
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Table 1 A summary of the TASQ
Domain Questions Maximum points
Physical symptoms 1,14 14
Physical limitations 3, 6, 7, 15 28
Emotional impact 2, 8, 9, 10, 11, 12, 13 49
Emotional impact and 
expectations
16 7
Social limitations 4, 5 14
  Total score=112
TASQ, Toronto Aortic Stenosis Quality of Life Questionnaire.
QoL and their expectations for the TAVI procedure, as 
well as their psychological coping, as part of their TAVI 
workup. Patients were asked to identify factors that they 
felt impacted their overall QoL. The factors were catego-
rised as emotional, physical, symptoms or social limita-
tions. Study participants’ charts were reviewed to estab-
lish frequent themes of concern. Of the interviewed 
population, 211 patients underwent the TAVI procedure, 
89 were declined for TAVI and 38 were still waiting for 
their TAVI at the time of chart review. Overall, patients 
had an average age of 80 years and 54.5% (n=115) of the 
patients were male.
Common physical symptoms identified were fatigue 
and shortness of breath, while completion of household 
chores and bathing were the most frequently identi-
fied physical limitations. Factors described as having an 
emotional impact included fear of a cardiac event, frus-
tration with repeated admissions to hospital or visits to 
the emergency department, worry about maintaining 
their independence, inability to care for a dependent 
relative and distress that they were no longer able to plan 
for the future. The main social limitations included that 
the patient was no longer able to participate in social 
events or to socialise with friends as they had previously. 
The area of most concern was being able to meet with 
family members.
The prototype TASQ was assessed in a small study 
comprising 62 participants, using the KCCQ and IIRS 
scales for comparative purposes. The scoring of the 
TASQ was based on a consistent 7 point scale for each 
question, which covers response options from ‘not very 
much’ to ‘very much’. Preliminary data showed that in 
this small number of patients there was good alignment 
of the TASQ with the KCCQ and IIRS scales.18 The final 
version of the TASQ questionnaire included a total of 16 
questions from five domains (table 1). Each question has 
a maximum score of 7, giving the complete questionnaire 
a maximum total score of 112. The full questionnaire is 
provided in the (online supplementary file 1).
study objectives
The primary objective of the registry is to validate the 
TASQ questionnaire in patients with severe symptomatic 
AS undergoing TAVI, SAVR or medical management 
in the five aforementioned different languages. The 
secondary objective is to assess the utility of the TASQ 
questionnaire for assessing differences in QoL outcome 
between patients undergoing TF-TAVI, SAVR or medical 
management for their AS. Further objectives are to 
compare the TASQ and its specific items with other 
non-dedicated questionnaires that are us in patients 
undergoing aortic valve replacement (ie, perception of 
autonomy, functional capacity, fear of dying, social life, 
etc). Further exploratory objectives include the assess-
ment of the impact of the ejection fraction on the QoL in 
the context of the TASQ.
study population
At each of the participating centres, patients will be 
consecutively enrolled if they have severe symptomatic 
AS and have been scheduled to undergo elective TF-TAVI 
or SAVR. Patients who are to be treated medically will be 
enrolled for comparison purposes. The treatment deci-
sion will be made by the heart team at each centre, based 
on standard in-house protocols, and will be independent 
of the study. Patients with major cognitive impairment 
and those who are unable to provide written informed 
consent will be excluded from the study.
Data collection
All data will be recorded on an electronic case report form 
(eCRF). At baseline, the eCRF will capture risk factors, 
pre-existing medical conditions, psychiatric disorders, 
ejection fraction and New York Heart Association class. 
Additional information for the eCRF includes answers 
of the TASQ, KCCQ and SF-12 questionnaires (adminis-
tered by research staff), patient demographic and clinical 
characteristics, employment status, living arrangements, 
activities of daily living and details of the procedure and 
postprocedural care (including plans for discharge and 
length of hospital stay) documented on the day of the 
TAVI/SAVR intervention. The questionnaires will be 
completed at baseline, predischarge, as well as at 30 days 
and 3 months follow-up. The schedule for data collection 
is given in table 2.
The study nurse will receive a login and secret password 
on centre initiation to access the site and enter data. The 
eCRF has been designed to allow for automatic checks 
for plausibility and completeness. Data monitoring will 
be implemented by the sponsor. Two centres will be 
randomly selected, and approximately 20% of all patients 
will be assessed for accuracy.
statistical analysis
The internal consistency of items in the TASQ will be 
measured using Cronbach’s alpha. Construct validity will 
be correlated with the KCCQ. Floor effects will be calcu-
lated by comparing the number of patients scoring the 
worst possible score with the TASQ to the number of the 
patients scoring the worst possible score on the KCCQ. 
Ceiling effects will be calculated in the same manner.
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Table 2 Data collection schedule
Baseline Intervention Predischarge 30 days 3 months
Patient information/informed consent X
Demographics X
Employment status, living arrangements, activities of daily living X
Comorbidities* X
Psychiatric disorders† X
Procedural details  X
Procedural outcomes  X
Discharge plans, postprocedure length of stay  X
Outcomes (MACCE)  X X X
Anticipated further interventions‡  X X X
Delirium postprocedure  X X X
TASQ X X X X
KCCQ X X X X
SF-12 X X X X
*In particular, respiratory and cardiac conditions.
†Including present diagnosis of anxiety disorder or depression.
‡For example, transplant surgery.
KCCQ, Kansas City Cardiomyopathy Questionnaire; MACCE, major adverse cardiac and cerebrovascular events; SF-12, Short Form-12 
questionnaire; TASQ, Toronto Aortic Stenosis quality of life Questionnaire.
Responsiveness and sensitivity to change before and 
after the TAVI/SAVR procedures and at the follow-up 
time points will be analysed with paired t-tests. Further-
more, t-tests will be used to compare baseline to predis-
charge, 30 days and 3 months outcomes and to compare 
30 days to 3 months in terms of both QoL and patient 
expectations.
Changes between predischarge, 30 days and 3 months 
test results will measure responsiveness and sensitivity 
to change. Independent sample t-tests will be used to 
assess significant differences in the TASQ regarding QoL 
and symptom stability between the TF-TAVI and SAVR 
procedures.
Lastly, comparison analysis of QoL among the three 
QoL tools (TASQ, KCCQ and SF-12) and between 
TF-TAVI and SAVR patients will identify interactions 
between procedural group and measurement tool.
DIsCussIon
Patient QoL is increasingly being investigated as an 
outcome after the treatment of chronic disease. This is 
particularly relevant for patients with severe AS, who often 
have a short life expectancy. It is essential, therefore, that 
QoL be considered when weighing up the relative risks 
and benefits of the different strategies for managing AS.
Significant improvements in QoL have been demon-
strated for patients with severe AS who undergo 
SAVR19 20 or TAVI.21–23 Arnold et al used the KCCQ, 
SF-12 and EQ-5D questionnaires to evaluate QoL in 
patients before and after SAVR and TAVI, and reported 
improvements in all three measures at 1, 6 and 12 
months after postprocedure.15 An analysis of TAVI 
versus SAVR in the PARTNER trial found that KCCQ, 
SF-12 and EQ-5D scores improved after both proce-
dures, with TAVI via TF access demonstrating a slight 
advantage over SAVR in the short term.24 In a second 
cohort of the placement of aortic transcatheter valves 
(PARTNER) trial, patients who were unsuitable for 
SAVR were randomised to TAVI or medical manage-
ment. QoL was found to improve in both groups; 
however, the TAVI patients exhibited much greater 
improvements, with the difference between groups 
increasing over time.25 As the strongest improvement of 
the QoL was seen within the first week/months after the 
intervention, we opted for a 1 and 3-month follow-up 
in our project in an effort to keep the study design as 
pragmatic and focused as possible. We acknowledge the 
value of longer follow-ups, however.
While the questionnaires used in these studies to assess 
QoL in patients with severe AS have been demonstrated 
to have validity, they each have significant shortcom-
ings. The KCCQ, although related to cardiac symptoms, 
is highly specific to HF, with every question reiterating 
this point.9 Furthermore, most questions refer to one 
or more HF-specific symptoms, including shortness of 
breath, fatigue and swelling of the ankles/feet. While 
these are also symptoms associated with severe AS, there 
are further factors that may affect the QoL of this elderly, 
multimorbid population. An important additional disad-
vantage of the KCCQ is the limited accuracy with which 
it can capture changes in QoL resulting from aortic valve 
replacement. Again, the questions are symptom specific, 
and do not encompass other more general QoL variables, 
such as mobility. They also fail to take into account the 
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Protocol
psychological implications prior to and after undergoing 
an intervention such as SAVR or TAVI.
On the other hand, the SF-12 refers to general 
health-related QoL.13 The only specific symptom that 
is mentioned is pain, which is unlikely to be among the 
most significant factors affecting the QoL in patients 
with severe AS. As patients with AS are generally elderly, 
many will have comorbidities and problems associated 
with frailty.26 In this setting, the SF-12 is not equipped to 
separate the effects of the AS from those of other condi-
tions. The SF-12 has the advantage that it incorporates a 
number of general questions related to emotional and 
psychological issues associated with poor health; however, 
again, these are not specific to the AS patient population.
The TASQ was carefully designed in order to overcome 
the shortcomings of the currently available health-re-
lated QoL questionnaires. By incorporating insight from 
patients with severe AS, this novel assessment tool was 
developed to address the physical, emotional and social 
factors associated with this specific condition. The TASQ 
allows the patient to evaluate the effect of their ‘heart 
problems’ on QoL, without specifying the symptoms that 
should form the basis for their conclusion. It includes a 
number of questions related to the implications of AS 
and its treatment on the patient’s future; for example, 
concerns regarding family or finances.
An important element of the TASQ is the evaluation 
of changes in QoL that have occurred within the last 2 
months. This allows for assessment of how the valve replace-
ment itself has affected the patient’s QoL. Completion of 
the questionnaires at discharge from hospital will be used 
to investigate any immediate changes in QoL resulting 
from the valve intervention, while those completed at 30 
days and 3 months follow-up will provide an indication of 
the longer-term outlook after the procedure.
The ability to more accurately assess the QoL of patients 
undergoing treatment for severe AS will enable more 
appropriate treatment decisions to be made. Further-
more, it may help to identify specific concerns associ-
ated with the different therapies. These could then be 
addressed, for example, with rehabilitation, counselling 
or home care assistance.
Potential limitations
We elected to oversample due to attrition of patients 
during clinical trials. We also opted for a larger sample 
number to ensure stable data given that we were looking 
at cross language reliability and reproducibility. The 
sample size used non-probability sampling and was based 
on the envisaged recruitment rate during the enrol-
ment period, which would allow for equal distribution of 
patient numbers across languages.
A further issue is that patients will be asked to complete 
three separate questionnaires, the inconvenience of 
which may result in missing answers. In order to spread the 
burden of this across the three forms, they will be admin-
istered to the patients in a random order. To address this 
possible problem, all patients will be evaluated for their 
compliance and ability to participate to the study in order 
to maximise the probability of complete follow-up.
Finally, we opted to go for TF-TAVI patients, as it is the 
standard access route in each of the centres. The docu-
mentation of non-TF patients would have a limited impact 
on clinical decision making (as TF-TAVI is standard) and 
would have potentially delayed recruitment substantially.
ConClusIon
The TASQ was developed to address the absence of a 
QoL measure for patients with severe AS. The short 
life expectancy of this elderly, multimorbid population 
places greater emphasis on improving QoL, in contrast 
with the usual treatment aim of extending survival. It 
will also provide important information related to the 
patients and his family perception of the therapy value. 
This is essential in when the reimbursement of thera-
peutic options will be evaluated according to the patient 
satisfaction and perception of care value.
author affiliations
1Departmentof Internal Medicine III (Cardiology, Angiology and Intensive Care 
Medicine), UKSH University Clinical Center Schleswig-Holstein, Kiel, Germany and 
DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/
Lübeck, Kiel, Germany
2Department of Cardiology, Barts Heart Centre, St. Bartholomew’s Hospital London, 
London, UK
3Departmentof Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria
4Departmentof Thoracic and Cardiovascular Surgery, Department of Interventional 
Cardiology, Hopital Privé Jacques Cartier, Massy, France
5Department of Structural Interventional Cardiology, Department of Cardiac Surgery, 
Careggi University Hospital, Florence, Italy
6Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy
7Department of Cardiology, Bichat-Claude Bernard Hospital, Paris, France
8Department of Cardiology, Department of Cardiovascular Surgery, Hospital Juan 
Canalejo, Coruña, Spain
9Department of Cardiology, Hospital Vall d’Hebron, Barcelona, Spain
10Edwards Lifesciences, Prague, Czech Republic
11Edwards Lifesciences, Nyon, Switzerland
12Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
13Department of Psychiatry, University Health Network, Toronto, Ontario, Canada
acknowledgements Data were captured using the s4trials software provided by 
software for Trials Europe, Berlin, Germany.
Contributors DF, SK, TL, CL, PB and RS were involved in the conception and 
design of the registry. The remaining authors gave feedback on the final protocol 
and are currently including patients. DF, CL and PB drafted the manuscript and all 
other authors have been revising the article for important intellectual content. All 
authors have given final approval of the version to be published. All authors are 
fully accountable for the content of the manuscript.
Funding A research grant provided by Edwards Lifesciences (Nyon, Switzerland) 
to the Institute for Pharmacology and Preventive Medicine (Cloppenburg, Germany).
Competing interests PB is the representative of the Institute for Pharmacology 
and Preventive Medicine, Cloppenburg, Germany. All centres were paid by IPPMed 
for the enrolment and documentation of patients.
Patient consent for publication Not required.
ethics approval The study protocol will be submitted to the relevant Independent 
Ethics Committee or Institutional Review Board at each centre for approval. The 
registry for this validation protocol will be in accordance with the Declaration of 
Helsinki and its amendments, as well as country-specific laws and regulations.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement There are no data in this work.
 o
n
 11 July 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2019-001008 on 21 M
ay 2019. Downloaded from
 
Open Heart
6 Frank D, et al. Open Heart 2019;6:e001008. doi:10.1136/openhrt-2019-001008
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
RefeRences
 1. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines 
for the management of valvular heart disease. Eur Heart J 
2017;38:2739–91.
 2. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve 
implantation for aortic stenosis in patients who cannot undergo 
surgery. N Engl J Med Overseas Ed 2010;363:1597–607.
 3. Bonaros N, Petzina R, Cocchieri R, et al. Transaortic transcatheter 
aortic valve implantation as a first-line choice or as a last resort? 
An analysis based on the route registry. Eur J Cardiothorac Surg 
2017;51:919–26.
 4. Arnold SV, Spertus JA, Lei Y, et al. How to define a poor outcome 
after transcatheter aortic valve replacement: conceptual framework 
and empirical observations from the placement of aortic 
transcatheter valve (partner) trial. Circ Cardiovasc Qual Outcomes 
2013;6:591–7.
 5. Kundi H, Strom JB, Valsdottir LR, et al. Trends in Isolated 
Surgical Aortic Valve Replacement According to Hospital-Based 
Transcatheter Aortic Valve Replacement Volumes. JACC Cardiovasc 
Interv 2018;11:2148–56.
 6. Lancellotti P, Magne J, Dulgheru R, et al. Outcomes of patients with 
asymptomatic aortic stenosis followed up in heart valve clinics. 
JAMA Cardiol 2018;3.
 7. Shi S, Afilalo J, Lipsitz LA, et al. Frailty phenotype and deficit 
accumulation frailty index in predicting recovery after transcatheter 
and surgical aortic valve replacement. The Journals of Gerontology: 
Series A 2018;62.
 8. Devins GM. Using the illness intrusiveness ratings scale to 
understand health-related quality of life in chronic disease. J 
Psychosom Res 2010;68:591–602.
 9. Green CP, Porter CB, Bresnahan DR, et al. Development and 
evaluation of the Kansas City cardiomyopathy questionnaire: a 
new health status measure for heart failure. J Am Coll Cardiol 
2000;35:1245–55.
 10. Spertus JA, Winder JA, Dewhurst TA, et al. Development and 
evaluation of the Seattle angina questionnaire: a new functional 
status measure for coronary artery disease. J Am Coll Cardiol 
1995;25:333–41.
 11. Rector TS, Cohn JN. Assessment of patient outcome with The 
Minnesota living with heart failure questionnaire: reliability and 
validity during a randomized, double-blind, placebo-controlled trial 
of pimobendan. pimobendan multicenter Research Group. Am Heart 
J 1992;124:1017–25.
 12. Dixon T, Lim LLY, Oldridge NB. The MacNew heart disease health-
related quality of life Instrument: reference data for users. Qual Life 
Res 2002;11:173–83.
 13. Ware J, Kosinski M, Keller SD. A 12-Item short-form health survey: 
construction of scales and preliminary tests of reliability and validity. 
Med Care 1996;34:220–33.
 14. EuroQol Group. EuroQol--a new facility for the measurement of 
health-related quality of life. Health Policy 1990;16:199–208.
 15. Arnold SV, Reynolds MR, Wang K, et al. Health status after 
transcatheter or surgical aortic valve replacement in patients with 
severe aortic stenosis at increased surgical risk: results from the 
CoreValve us pivotal trial. JACC Cardiovasc Interv 2015;8:1207–17.
 16. Arnold SV, Spertus JA, Lei Y, et al. Use of the Kansas City 
cardiomyopathy questionnaire for monitoring health status in 
patients with aortic stenosis. Circ Heart Fail 2013;6:61–7.
 17. Arnold SV, Spertus JA, Vemulapalli S, et al. Quality-of-life outcomes 
after transcatheter aortic valve replacement in an unselected 
population: a report from the STS/ACC transcatheter valve therapy 
registry. JAMA Cardiol 2017;2:409–16.
 18. Toronto Aortic Stenosis Quality of Life Scale (TASQ). Development 
and psychometric quality of life properties in TAVI patients. Toronto 
Aortic Stenosis Quality of Life Scale, 2017.
 19. Folkmann S, Gorlitzer M, Weiss G, et al. Quality-of-life in 
octogenarians one year after aortic valve replacement with or 
without coronary artery bypass surgery. Interact Cardiovasc Thorac 
Surg 2010;11:750–3.
 20. Oliveira SM, Correia AS, Paiva M, et al. Long-term survival, 
autonomy, and quality of life of elderly patients undergoing aortic 
valve replacement. J Card Surg 2012;27:20–3.
 21. Biermann J, Horack M, Kahlert P, et al. The impact of transcatheter 
aortic valve implantation on quality of life: results from the German 
transcatheter aortic valve interventions registry. Clin Res Cardiol 
2015;104:877–86.
 22. Bona V, Khawaja MZ, Bapat V, et al. Early and late changes in 
quality of life following transcatheter aortic valve implantation using 
the transfemoral and transapical approaches. EuroIntervention 
2015;11:221–9.
 23. Fairbairn TA, Meads DM, Mather AN, et al. Serial change in health-
related quality of life over 1 year after transcatheter aortic valve 
implantation: predictors of health outcomes. J Am Coll Cardiol 
2012;59:1672–80.
 24. Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of 
life after transcatheter or surgical aortic valve replacement in high-
risk patients with severe aortic stenosis: results from the partner 
(placement of aortic transcatheter valve) trial (cohort a). J Am Coll 
Cardiol 2012;60:548–58.
 25. Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of life 
after transcatheter aortic valve replacement in inoperable patients 
with severe aortic stenosis. Circulation 2011;124:1964–72.
 26. Díez-Villanueva P, Salamanca J, Rojas A, et al. Importance of frailty 
and comorbidity in elderly patients with severe aortic stenosis. J 
Geriatr Cardiol 2017;14:379–82.
 o
n
 11 July 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2019-001008 on 21 M
ay 2019. Downloaded from
 
